New online tool aims to pick the right patients for cancer drug trials
NCT ID NCT07593053
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
Researchers tested a new online tool called PIPO that helps doctors estimate how long a cancer patient might live. This information can guide decisions about which patients to enroll in early-phase clinical trials. The study included 586 people who had already joined phase 1 or phase 2 trials. The goal is to make trial participation safer and more effective by avoiding treatments in patients who may not live long enough to benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this tool could help doctors better choose which patients are most likely to benefit from early-phase cancer trials, making the process safer and more efficient.
What could go wrong
This is a completed observational study, not a treatment trial. The tool may not work perfectly for all patients or cancer types, and it does not directly improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCOLOGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vall d'Hebron Institue of Oncology
Barcelona, Spain